Elotuzumab Biosimilar(Anti-SLAMF7 / CS1 Reference Antibody) Datasheet DC Chemicals
Description
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.